W. Adam Hill is the Chief Technology Officer of Triple Sharp Venture Engineering, LLC. He is focused on positively impacting patients’ lives and bringing efficiency and effectiveness to discovering new medicines. Adam is a pioneer in the implementation of new technologies to effect greater efficiencies in life sciences. Prior to joining Triple Sharp, Adam served as a long-time head of drug screening for Novartis, one of the top pharmaceutical companies in the world. In this role, Adam advanced new compounds into clinical development and evaluated new drug discovery technologies. He also served as a managing scientist at Millennium Pharmaceuticals and Schering-Plough. Adam received his D. Phil, Chemistry & Pharmacology, from the University of Oxford and conducted post-doctoral research at Harvard University and the University of Connecticut.